ResMed/RMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About ResMed
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Ticker
RMD
Sector
Healthcare
Trading on
NYSE
Industry
Health Care Equipment and Supplies
Headquarters
San Diego, United States
Employees
10,140
Website
www.resmed.com
ResMed Metrics
BasicAdvanced
$27B
Market cap
28.76
P/E ratio
$6.50
EPS
0.67
Beta
$1.88
Dividend rate
1.01%
Dividend yield
Price and volume
Market cap
$27B
Beta
0.67
Dividend rate
$1.88
Financial strength
Current ratio
3.042
Quick ratio
1.393
Long term debt to equity
24.479
Total debt to equity
25.215
Dividend payout ratio (TTM)
28.85%
Interest coverage (TTM)
23.55%
Management effectiveness
Return on assets (TTM)
11.91%
Return on equity (TTM)
22.39%
Valuation
Price to earnings (TTM)
28.76
Price to revenue (TTM)
6
Price to book
5.93
Price to tangible book (TTM)
21.23
Price to free cash flow (TTM)
25.66
Dividend yield (TTM)
1.01%
Growth
Revenue change (TTM)
14.16%
Earnings per share change (TTM)
10.91%
3-year revenue growth
14.04%
3-year earnings per share growth
27.60%
3-year dividend per share growth
6.42%
What the Analysts think about ResMed
Analyst Ratings
Majority rating from 15 analysts.
ResMed Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$1.2B
2.93%
Net income
$300M
43.87%
Profit margin
25.09%
39.78%
ResMed Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$1.60
$1.64
$1.88
$2.13
-
Expected
$1.69
$1.62
$1.80
$1.91
$2.06
Surprise
-5.37%
1.42%
4.70%
11.34%
-
ResMed News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ResMed stock?
ResMed (RMD) has a market cap of $27B as of July 03, 2024.
What is the P/E ratio for ResMed stock?
The price to earnings (P/E) ratio for ResMed (RMD) stock is 28.76 as of July 03, 2024.
Does ResMed stock pay dividends?
Yes, the ResMed (RMD) stock pays dividends to shareholders. As of July 03, 2024, the dividend rate is $1.88 and the yield is 1.01%. ResMed has a payout ratio of 28.85% on a trailing twelve-month basis.
When is the next ResMed dividend payment date?
The next ResMed (RMD) dividend payment date is unconfirmed.
What is the beta indicator for ResMed?
ResMed (RMD) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell ResMed stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.